Kurt L. Pflieger, M.D.; Order Dismissing Order To Show Cause, 2577-2578 [2019-01528]

Download as PDF 2577 Federal Register / Vol. 84, No. 26 / Thursday, February 7, 2019 / Notices Registrants listed below have applied for and been granted registration by-the Drug Enforcement Administration (DEA) as importers of various classes of schedule I or II controlled substances. SUMMARY: DEPARTMENT OF JUSTICE Drug Enforcement Administration [Docket No. DEA–392] Importer of Controlled Substances Registration ACTION: classes of controlled substances. Information on previously published notices is listed in the table below. No comments or objections were submitted and no requests for hearing were submitted for these notices. The companies listed below applied to be registered as importers of various basic SUPPLEMENTARY INFORMATION: Notice of registration. Company FR docket Noramco Inc ...................................................................................................................................................... Catalent CTS, LLC ............................................................................................................................................ United States Pharmacopeial Convention ........................................................................................................ Fisher Clinical Services, Inc ............................................................................................................................. Cambrex High Point, Inc ................................................................................................................................... Sharp (Bethlehem), LLC ................................................................................................................................... The DEA has considered the factors in 21 U.S.C. 823, 952(a) and 958(a) and determined that the registration of the listed registrants to import the applicable basic classes of schedule I or II controlled substances is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971. The DEA investigated each company’s maintenance of effective controls against diversion by inspecting and testing each of the company’s physical security systems, verifying each company’s compliance with state and local laws, and reviewing each company’s background and history. Therefore, pursuant to 21 U.S.C. 952(a) and 958(a), and in accordance with 21 CFR 1301.34, the DEA has granted a registration as an importer for schedule I or II controlled substances to the above listed companies. Dated: December 21, 2018. John J. Martin, Assistant Administrator. 83 83 83 83 83 83 FR FR FR FR FR FR 53107 54613 54611 54612 54610 54612 The companies listed below applied to be registered as bulk manufacturers of various basic classes of controlled substances. Information on previously published notices is listed in the table below. No comments or objections were submitted for these notices. BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Drug Enforcement Administration [Docket No. DEA–392] Bulk Manufacturer of Controlled Substances Registration ACTION: Notice of registration. 83 FR 48334 83 FR 49578 Jkt 247001 2018. 2018. 2018. 2018. 2018. 2018. SUPPLEMENTARY INFORMATION: [FR Doc. 2019–01519 Filed 2–6–19; 8:45 am] AMPAC Fine Chemicals Virginia, LLC .......................................................................................................... AMPAC Fine Chemicals, LLC ....................................................................................................................... 17:23 Feb 06, 2019 19, 30, 30, 30, 30, 30, The registrants listed below has applied for and has been granted registration by the Drug Enforcement Administration (DEA) as bulk manufacturer of various classes of schedule I and II controlled substances. FR Docket VerDate Sep<11>2014 October October October October October October SUMMARY: Company The DEA has considered the factors in 21 U.S.C. 823(a) and determined that the registration of this registrant to manufacture the applicable basic classes of controlled substances is consistent with the public interest and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971. The DEA investigated the company’s maintenance of effective controls against diversion by inspecting and testing their physical security systems, verifying their compliance with state and local laws, and reviewing each of the company’s background and history. Therefore, pursuant to 21 U.S.C. 823(a), and in accordance with 21 CFR 1301.33, the DEA has granted a Published registration as a bulk manufacturer to the above listed companies. Dated: December 21, 2018. John J. Martin, Assistant Administrator. [FR Doc. 2019–01525 Filed 2–6–19; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Drug Enforcement Administration [Docket No. 2018–43] Kurt L. Pflieger, M.D.; Order Dismissing Order To Show Cause On July 12, 2018, the Assistant Administrator, Diversion Control Division, Drug Enforcement PO 00000 Frm 00091 Fmt 4703 Sfmt 4703 Published September 24, 2018. October 2, 2018. Administration (hereinafter, DEA or Government), issued an Order to Show Cause to Kurt L. Pflieger, M.D. (hereinafter, Respondent), of Rockwall, Texas. Order to Show Cause (hereinafter, OSC), at 1. The OSC proposes the revocation of Respondent’s Certificate of Registration on the ground that he does not have authority to handle controlled substances in the State of Texas, the State in which he is registered with the DEA. Id. After the Administrative Law Judge (hereinafter, ALJ) certified and transmitted the record to me along with his Recommended Decision, the Government submitted a ‘‘Motion to Dismiss Order to Show Cause’’ (hereinafter, Motion). According to the Motion, the Texas Medical Board held E:\FR\FM\07FEN1.SGM 07FEN1 2578 Federal Register / Vol. 84, No. 26 / Thursday, February 7, 2019 / Notices a hearing after the ALJ granted the Government’s Motion for Summary Disposition and recommended revocation of Respondent’s registration. Motion, at 1. The Motion also states that, as a result of the hearing, the Texas Medical Board suspended Respondent’s medical license, ordered that the suspension be stayed, and placed Respondent on five years’ probation under various terms and conditions. Id. The Motion concludes by stating that, ‘‘Since . . . [Respondent] now has state authority to handle controlled substances, the DEA respectfully request[s] the Administrator to dismiss the pending Order to Show Cause and recommended ruling from the Administrative Law Judge.’’ Id. at 2. Accordingly, I shall dismiss the Order to Show Cause. Order Pursuant to 28 CFR 0.100(b) and the authority thus vested in me by 21 U.S.C. 823(f) and 824(a), I order that the Order to Show Cause issued to Kurt L. Pflieger, M.D. be, and it hereby is, dismissed. This Order is effective March 11, 2019. Dated: January 17, 2019. Uttam Dhillon, Acting Administrator. [FR Doc. 2019–01528 Filed 2–6–19; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Drug Enforcement Administration [Docket No. DEA–392] Importer of Controlled Substances Application: Chattem Chemicals ACTION: Notice of application. Registered bulk manufacturers of the affected basic classes, and applicants therefore, may file written comments on or objections to the issuance of the proposed registration on or before March 11, 2019. Such persons may also file a written request for a hearing on the application on or before March 11, 2019. ADDRESSES: Written comments should be sent to: Drug Enforcement Administration, Attention: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152. All requests for hearing must be sent to: Drug Enforcement Administration, Attn: Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152. All requests for hearing should also be sent to: (1) Drug Enforcement Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette Drive, Springfield, Virginia 22152; and (2) Drug Enforcement Administration, Attn: DEA Federal Register DATES: Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152. The Attorney General has delegated his authority under the Controlled Substances Act to the Administrator of the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority to exercise all necessary functions with respect to the promulgation and implementation of 21 CFR part 1301, incident to the registration of manufacturers, distributors, dispensers, importers, and exporters of controlled substances (other than final orders in connection with suspension, denial, or revocation of registration) has been redelegated to the Assistant Administrator of the DEA Diversion Control Division (‘‘Assistant Administrator’’) pursuant to section 7 of 28 CFR part 0, appendix to subpart R. In accordance with 21 CFR 1301.34(a), this is notice that on October 31, 2018, Chattem Chemicals Inc., 3801 Saint Elmo Avenue, Chattanooga, Tennessee 37409–1237 applied to be registered as an importer of the following basic classes of controlled substances: SUPPLEMENTARY INFORMATION: Drug code Controlled substance Methamphetamine ................................................................................................................................................................... 4-Anilino-N-phenethyl-4-piperidine (ANPP) ............................................................................................................................. Phenylacetone ......................................................................................................................................................................... Opium, raw .............................................................................................................................................................................. Poppy Straw Concentrate ....................................................................................................................................................... Tapentadol ............................................................................................................................................................................... The company plans to import the listed controlled substances to manufacture bulk controlled substances for sale to its customers. The company plans to import an intermediate of tapentadol (9780), to bulk manufacture tapentadol for distribution to its customers. DEPARTMENT OF JUSTICE Dated: December 21, 2018. John J. Martin, Assistant Administrator. ACTION: Drug Enforcement Administration [Docket No. DEA–392] Bulk Manufacturer of Controlled Substances Registration Notice of registration. Registrants listed below have applied for and been granted a registration by the Drug Enforcement Administration (DEA) as bulk SUMMARY: [FR Doc. 2019–01512 Filed 2–6–19; 8:45 am] BILLING CODE 4410–09–P The companies listed below applied to be registered as bulk manufacturers of various basic classes of controlled substances. Information on previously published notices are listed in the table below. No comments or objections were submitted for these notices. SUPPLEMENTARY INFORMATION: FR Docket National Center for Natural Products Research NIDA MPROJECT ............................................................ Halo Pharmaceutical, Inc .............................................................................................................................. Nanosyn, Inc ................................................................................................................................................. 83 FR 48334 83 FR 48334 83 FR 48867 17:23 Feb 06, 2019 Jkt 247001 PO 00000 Frm 00092 Fmt 4703 Sfmt 4703 II II II II II II manufacturers of various classes of schedule I and II controlled substances. Company VerDate Sep<11>2014 1105 8333 8501 9600 9670 9780 Schedule E:\FR\FM\07FEN1.SGM 07FEN1 Published August 31, 2018. September 24, 2018. September 27, 2018.

Agencies

[Federal Register Volume 84, Number 26 (Thursday, February 7, 2019)]
[Notices]
[Pages 2577-2578]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-01528]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. 2018-43]


Kurt L. Pflieger, M.D.; Order Dismissing Order To Show Cause

    On July 12, 2018, the Assistant Administrator, Diversion Control 
Division, Drug Enforcement Administration (hereinafter, DEA or 
Government), issued an Order to Show Cause to Kurt L. Pflieger, M.D. 
(hereinafter, Respondent), of Rockwall, Texas. Order to Show Cause 
(hereinafter, OSC), at 1. The OSC proposes the revocation of 
Respondent's Certificate of Registration on the ground that he does not 
have authority to handle controlled substances in the State of Texas, 
the State in which he is registered with the DEA. Id.
    After the Administrative Law Judge (hereinafter, ALJ) certified and 
transmitted the record to me along with his Recommended Decision, the 
Government submitted a ``Motion to Dismiss Order to Show Cause'' 
(hereinafter, Motion). According to the Motion, the Texas Medical Board 
held

[[Page 2578]]

a hearing after the ALJ granted the Government's Motion for Summary 
Disposition and recommended revocation of Respondent's registration. 
Motion, at 1. The Motion also states that, as a result of the hearing, 
the Texas Medical Board suspended Respondent's medical license, ordered 
that the suspension be stayed, and placed Respondent on five years' 
probation under various terms and conditions. Id.
    The Motion concludes by stating that, ``Since . . . [Respondent] 
now has state authority to handle controlled substances, the DEA 
respectfully request[s] the Administrator to dismiss the pending Order 
to Show Cause and recommended ruling from the Administrative Law 
Judge.'' Id. at 2. Accordingly, I shall dismiss the Order to Show 
Cause.

Order

    Pursuant to 28 CFR 0.100(b) and the authority thus vested in me by 
21 U.S.C. 823(f) and 824(a), I order that the Order to Show Cause 
issued to Kurt L. Pflieger, M.D. be, and it hereby is, dismissed. This 
Order is effective March 11, 2019.

    Dated: January 17, 2019.
Uttam Dhillon,
Acting Administrator.
[FR Doc. 2019-01528 Filed 2-6-19; 8:45 am]
 BILLING CODE 4410-09-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.